Prosecution Insights
Last updated: November 21, 2026
Application No. 18/867,060

CONCENTRATED CONDITIONING COMPOSITIONS

Final Rejection §103§112
Filed
Nov 19, 2024
Priority
May 27, 2022 — provisional 63/346,351 +2 more
Examiner
PURDY, KYLE A
Art Unit
1611
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Conopco, Inc. d/b/a Unilever
OA Round
2 (Final)
41%
Grant Probability
Moderate
3-4
OA Rounds
2y 1m
Est. Remaining
77%
With Interview

Examiner Intelligence

Grants 41% of resolved cases
41%
Career Allowance Rate
410 granted / 1004 resolved
-19.2% vs TC avg
Strong +36% interview lift
Without
With
+35.8%
Interview Lift
resolved cases with interview
Typical timeline
4y 1m
Avg Prosecution
80 currently pending
Career history
1094
Total Applications
across all art units

Statute-Specific Performance

§101
1.4%
-38.6% vs TC avg
§103
62.8%
+22.8% vs TC avg
§102
13.8%
-26.2% vs TC avg
§112
14.3%
-25.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1004 resolved cases

Office Action

§103 §112
DETAILED ACTION Status of Application The Examiner acknowledges receipt of the amendments filed on 9/30/2026 wherein claims 1, 4 and 15 have been amended. Claims 1-15 are presented for examination on the merits. The following rejections are made. Information Disclosure Statement The information disclosure statement (IDS) submitted on 9/30/2026 was considered by the examiner. Response to Applicants’ Arguments Applicant’s amendments/arguments filed 9/30/2026 overcomes the rejection of claims 4, 12 and 15 made by the Examiner under 35 USC 112(b). This rejection has been overcome by amendment. Applicant’s amendments/arguments filed 9/30/2026 overcomes the rejection of claim 15 made by the Examiner under 35 USC 112(d). This rejection has been overcome by amendment. Applicant’s amendments/arguments filed 9/30/2026 overcome the rejection of claims 1-9 and 12-15 made by the Examiner under 35 USC 102(a)(1) over Glenn Jr et al. (US 2019/0328630). This rejection has been withdrawn as Glenn fails to describe the presently claimed viscosity. Applicant’s arguments filed 9/30/2026 regarding the rejection of claims 1-15 made by the Examiner under 35 USC 103 over Glenn Jr et al. (US 2019/0328630) in view of Cornwell et al. (US 2019/0070087). This rejection has been withdrawn as Glenn fails to describe the presently claimed viscosity. New Rejections, Necessitated by Amendment Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1-9 and 12-15 is/are rejected under 35 U.S.C. 103 as being unpatentable over Glenn Jr. et al. (US 2019/0328630; of record) in view of Coan et al. (US 2020/0197273). Glenn provides a concentrated hair care conditioning composition comprising: from about 2-6% a fatty alcohol, such as cetyl alcohol (an C16 alcohol) and stearyl alcohol (an C18 alcohol) (see abstract, claim 1 and [0006, 0007] and Examples; see instant claims 1-3 and 13-14); from about 1-3% of a cationic surfactant such as behenyl trimethyl ammonium chloride (i.e. behentrimonium chloride) and cetyltrimethyl ammonium chloride (see [0095] and Examples; see instant claim 5; see instant claims 1 and 5) and cationic silicones comprising dimethicone, cyclomethicone and amodimethicone (see [0042, 0058-0061]; see instant claims 1 and 4); from about 1-2% thickening agents such as cationic polymers, e.g. vinylpyrrolidone (i.e. 1-vinyl-2-pyrrolidone) and dimethylaminoethyl methacrylate copolymers (see [0110]; see instant claim 6), and minerals such as bentonite and magnesium aluminum silicate (see [0109]; see instant claims 1 and 9); a polyol solvent such as propylene glycol and/or butylene glycol (see [0100]; see instant claim 1), other solvents include lactic acid citric acid, maleic acid and glycolic acid (see [0105]; see instant claims 7-8); and from about 75-95% water (see [0007], Examples and claim 1; see instant claim 1). Glenn fails to teach their concentrated conditioner composition as having a viscosity of between 200,000-700,000 centipoise. Coan, like Glenn, is directed to concentrated conditioning compositions. Exemplified compositions having the following composition: PNG media_image1.png 252 407 media_image1.png Greyscale (see Table 3) wherein the compositions have a base viscosity (pre dilution) of 398,400 cP (centipoise) and 656/800 cP (see Table 4). The concentrated Coan composition is diluted with water (e.g. 2:1; see instant claims 12 and 15) so as to modulate the viscosity to a desirable level, e.g. 9,600 cP. Although Glenn teaches a maximum predilution composition viscosity of 10,000 cP, it would have been obvious to modify Glenn so as to further concentrate the composition thereby increasing its viscosity to a value such as that described by Coan (e.g. 398,400 cP) with a reasonable expectation that such a viscous composition could ultimately be diluted and used as hair conditioning product. The viscosity of the concentrated hair conditioning composition appears to be a matter of preference and a parameter which one of ordinary skill in the art would be capable of manipulating to ones’ own desires knowing that the composition is ultimately diluted so as to form a final end use conditioning product. See MPEP 2144.05(II)(A). Regarding instant claims 12 and 15, the level of concentration appears to be a relationship between the claimed composition and some other secondary composition. This comparison is an outcome of a dilution/concentration process which is an outcome of a product-by-process (see MPEP 2113) and thus not seen as limiting to the composition of the claims because the claimed composition itself is already well defined. How the claimed composition compares to some other composition is not relevant to or limiting of the composition as it does not provide any structural limitation to what is actually being claimed but instead provides a relationship of the claimed composition to some other non-claimed composition. Therefore, the invention as a whole is prima facie obvious to one of ordinary skill in the art at the time the invention was filed, as evidenced by the references, especially in absence of evidence to the contrary. Claims 10 and 11 are rejected under 35 U.S.C. 103 as being unpatentable over Glenn Jr. et al. (US 2019/0328630; of record) in view of Coan et al. (US 2020/0197273) as applied to claims 1-9 and 12-15 above, and further in view of Cornwell et al. (US 2019/0070087; of record). Glenn fails to teach their composition as comprising a hair repair agent such as glucono delta lactone, sodium gluconate, trehalose, sodium sulfate, or a combination thereof. Cornwell is directed to conditioning hair treatment compositions that comprise hair repair agents such as glucono delta lactone (see [0156] and claim 8) and a disaccharide such as trehalose (see claim 11). It is taught that lactones and disaccharides are useful in repairing hair as they provide protection prior to damage occurring thereby reducing damage from occurring as well as well as providing a repair benefit as well (see [0012, 0014]). Thus, it would have been obvious to modify Glenn’s so as to include lactones and disaccharides with a reasonable expectation for success in imparting hair repair benefit. See MPEP 2143(I)(A) which states combining prior art elements according to known methods to yield predictable results is supportive of obviousness. See also MPEP 2144.06(I). Therefore, the invention as a whole is prima facie obvious to one of ordinary skill in the art at the time the invention was filed, as evidenced by the references, especially in absence of evidence to the contrary. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. Claim 15 is rejected under 35 U.S.C. 112(b) as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor regards as the invention. Claim 15, dependent from claim 1, recites, “…wherein the level of concentration is 2.0.”. Claim 1 does not refer to a “level of concentration” and so “the level of concentration“ lacks antecedent basis. The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claims 12 and 15 are rejected under 35 U.S.C. 112(d) as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claims 12 and 15 provide comparison via a “level of concentration” which is an outcome of a product-by-process (e.g. dilution, concentration) and thus not seen as limiting to the composition of the claims because the claimed composition itself is already well defined. How the claimed composition compares to some other composition is not relevant to or limiting of the composition as it does not provide any added structural limitation to what is actually being claimed but instead provides a relationship of the claimed composition to some other non-claimed composition. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to KYLE A PURDY whose telephone number is (571)270-3504. The examiner can normally be reached from 9AM to 5PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bethany Barham, can be reached on 571-272-6175. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). /KYLE A PURDY/Primary Examiner, Art Unit 1611
Read full office action

Prosecution Timeline

Nov 19, 2024
Application Filed
Jun 30, 2026
Non-Final Rejection mailed — §103, §112
Sep 30, 2026
Response Filed
Nov 13, 2026
Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12799095
N-acetylserotonin Derivatives as TrkB Activators and Uses Thereof
4y 0m to grant Granted Nov 17, 2026
Patent 12797412
PHARMACEUTICAL COMPOSITION FOR IMPROVING HEALTH, CURE ABNORMALITIES AND DEGENERATIVE DISEASE, ACHIEVE ANTI-AGING EFFECT OF THERAPY AND THERAPEUTIC EFFECT ON MAMMALS AND METHOD THEREOF
2y 5m to grant Granted Nov 17, 2026
Patent 12788710
CUSTOMIZED COSMETIC COMPOSITIONS, AND METHODS OF REJUVENATING AND UTILIZING CONDITIONED MEDIA AND/OR COMPONENTS THEREOF
4y 1m to grant Granted Nov 10, 2026
Patent 12778134
COMPOSTABLE ANTI-MICROBIAL FILM AND METHOD OF APPLYING FILM TO PACKAGING
4y 2m to grant Granted Nov 03, 2026
Patent 12779008
PROCESS FOR PURIFICATION OF MITRAGYNINE
3y 6m to grant Granted Nov 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
41%
Grant Probability
77%
With Interview (+35.8%)
4y 1m (~2y 1m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1004 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month